Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Double-Blind Randomized Study of ISIS 484137 in Hepatic Steatosis in Adults with Type 2 Diabetes
2017-003197-13Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Oct 2017
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in steatosis and type 2 diabetes mellitus (T2DM) comparing ISIS 484137 with Placebo (2 arms). Primary endpoint: Safety endpoints. Started Oct 2017; status: completed.
02
Drugs
IONIS-DGAT2Rx
03
Conditions
steatosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-003197-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003197-13.